NCT05526989View on ClinicalTrials.gov

Study of the Combination Dostarlimab With Niraparib In Patients With Penile Carcinoma

PHASE2RecruitingINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

December 28, 2022

Primary Completion Date

November 30, 2026

Study Completion Date

November 30, 2027

Conditions
Penile Carcinoma
Interventions
DRUG

Dostarlimab

300 mg Dostarlimb will be administered by IV, increasing to 1000 mg after cycle 4.

DRUG

Niraparib

200 mg Niraparib will be taken once daily by mouth days 1-21 of all cycles.

Trial Locations (2)

33612

RECRUITING

Moffitt Cancer Center, Tampa

77030

NOT_YET_RECRUITING

MD Anderson Cancer Center, Houston

Sponsors

Collaborators (1)

GlaxoSmithKline
All Listed Sponsors
collaborator

GlaxoSmithKline

INDUSTRY

lead

H. Lee Moffitt Cancer Center and Research Institute

OTHER

NCT05526989 - Study of the Combination Dostarlimab With Niraparib In Patients With Penile Carcinoma | Biotech Hunter | Biotech Hunter